Johnson & Johnson (ETR:JNJ)
Germany
· Delayed Price · Currency is EUR | Market Cap | 321.53B |
| Revenue (ttm) | 82.47B |
| Net Income (ttm) | 20.13B |
| Shares Out | n/a |
| EPS (ttm) | 8.29 |
| PE Ratio | 15.97 |
| Forward PE | 14.62 |
| Dividend | 4.62 (3.46%) |
| Ex-Dividend Date | May 27, 2025 |
| Volume | 2,897 |
| Average Volume | 2,981 |
| Open | 134.76 |
| Previous Close | 133.90 |
| Day's Range | 133.50 - 134.80 |
| 52-Week Range | 128.16 - 161.30 |
| Beta | 0.41 |
| RSI | 50.81 |
| Earnings Date | Jul 16, 2025 |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizo... [Read more]
Financial Performance
In 2024, Johnson & Johnson's revenue was $88.82 billion, an increase of 4.30% compared to the previous year's $85.16 billion. Earnings were $14.07 billion, a decrease of -59.99%.
Financial numbers in USD Financial StatementsNews
Johnson & Johnson Q2 Preview: Focus on tariff threat, MedTech softness
What's Next: Johnson & Johnson's Earnings Preview
Johnson & Johnson (NYSE: JNJ) is preparing to release its quarterly earnings on Wednesday, 2025-07-16. Here's a brief overview of what investors should keep in mind before the announcement. Analysts ...
Should You Buy Johnson & Johnson Stock Before July 16th?
Andrew Hill Dumps 38,000 Johnson & Johnson Shares in Q2 2025 Exit
Johnson & Johnson: Buy JNJ Stock Ahead of Its Upcoming Earnings?
Johnson & Johnson (NYSE:JNJ) is set to report its earnings on Wednesday, July 16, 2025. For traders focused on events, analyzing historical stock behavior surrounding earnings reports can be an import...
Wells Fargo, Citi, Netflix, J&J, and More Stocks to Watch This Week
Financials make up half of the 38 S&P 500 companies slated to report quarterly results this week. The week's big economic news will be the consumer price index for June.
Earnings week ahead: JPM, BAC, GS, MS, C, JNJ, TSM, ABT, PEP, MMM, SLB, UAL, NFLX, and more
:max_bytes(150000):strip_icc():format(jpeg)/INV_JPMorganChaseHQ_GettyImages-548207569-6747006d369b496ab4697e8b361ba6a6.jpg)
What To Expect in Markets This Week: Big Bank Earnings, June Inflation, Retail Sales Data
Coming up: Big bank earnings, June CPI inflation data, and U.S. retail sales, along with updates from TSMC, Netflix and Johnson & Johnson.
Mar Vista U.S. Quality Q2 2025 Top Contributors And Detractors
Microsoft, Broadcom, and Oracle were among the portfolio's top contributors for the quarter. Alternatively, Apple, Johnson & Johnson, and Berkshire Hathaway detracted from performance. Microsoft share...
Johnson & Johnson Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Johnson & Johnson (NYSE: JNJ) will release earnings results for the second quarter, before the opening bell on Wednesday, July 16. Analysts expect the New Brunswick, New Jersey-based company to repor...
Johnson & Johnson Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Johnson & Johnson JNJ will release earnings results for the second quarter, before the opening bell on Wednesday, July 16.
SeaStar Medical's QUELIMMUNE Wins Prestigious Award From The National Kidney Foundation, Former Winners Include Names Like Janssen, Merck and Otsuka
When it comes to unmet needs in the nephrology space, acute kidney injury remains a significant concern. That's particularly true regarding pediatric AKI – each year, about 4,000 children with AKI req...
3 To Watch Of 23 'Safer' July Dividends From 46 Fortune World's Most Admired Companies
I analyze the 50 Fortune World's Most Admired Companies, focusing on dividend-paying stocks and their yield-based investment potential. Three companies—Pfizer, BMW, and Singapore Airlines—currently me...
Turn $5,000 into $300,000 with Top Dividend Stocks Like JNJ, PEP, and UPS
The majority of investors do not have hundreds of thousands of dollars to place into the stock market. For many of us, every dollar matters. However, even with minimal funds, careful planning and cons...
P/E Ratio Insights for Johnson & Johnson
In the current session, the stock is trading at $155.97, after a 0.12% increase. Over the past month, Johnson & Johnson Inc. (NYSE: JNJ) stock increased by 0.25% , and in the past year, by 3.98% . Wi...
Johnson & Johnson's Outlook Clouded By $2 Billion Headwind
Johnson & Johnson (NYSE: JNJ) is set to release its second-quarter earnings on Wednesday, July 16. According to Benzinga Pro data, analysts estimate adjusted earnings of $2.68 per share and sales of ...
Johnson & Johnson's Outlook Clouded By $2 Billion Headwind
Johnson & Johnson JNJ is set to release its second-quarter earnings on Wednesday, July 16. According to Benzinga Pro data, analysts estimate adjusted earnings of $2.68 per share and sales of $22.85 bi...
Johnson & Johnson: What To Expect From The Upcoming Q2 Earnings?
Johnson & Johnson to report Q2 earnings on July 16. Here’s what to expect
Johnson & Johnson’s (NYSE: JNJ) business strategy for fiscal 2025 is focused on reducing the impact of patent expirations on its revenue. Anticipating sales to benefit from growth initiatives, includi...
Trump threatens impose up to 200% tariff on pharmaceuticals 'very soon'
President Donald Trump threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S. "very soon." But he suggested that those levies would not go into effect immediately, saying h...
Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others
Trump's "big beautiful" bill will also affect the pharmaceutical industry, while AI startups have pulled in the majority of digital health funding this year.
Johnson & Johnson seeks FDA nod for expanded use of Capylta
Supplemental new drug application submitted to U.S. FDA for CAPLYTA® (lumateperone) with data demonstrating significant schizophrenia relapse prevention compared to placebo
Submission is based on long-term Phase 3 data demonstrating 63 percent reduction in risk of relapse in adults with schizophrenia compared to placebo CAPLYTA® is FDA approved to treat schizophrenia and...
FDA Issues Early Alert For Johnson & Johnson's Abiomed Heart Pump Controllers
Johnson & Johnson’s (NYSE: JNJ) Abiomed has issued an Early Alert regarding its Automated Impella Controllers (AIC) for Impella heart pumps, a device crucial for patients with severe heart conditions...
